Clinical trials: Human Immunodeficiency Virus II Infection
HIV-1-infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably…
- Trial name
- HIV-1 (NCT04404049)
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Volunteers
- 39 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
- Conditions
- Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection
- Trial name
- anal HSIL HIV- (NCT05555862)
- Testing
- Artesunate
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Frantz Viral Therapeutics, LLC
HIV Infection
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
This study uses autologous (one's own) CD4 T cells modified with a viral vector expressing a genetic antisense targeting HIV, this vector is called VRX496.
- Trial name
- NCT00131560
- Testing
- VRX496-Modified Autologous T cells
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- VIRxSYS Corporation
HIV-1 Infection
To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults
The purpose of this phase II study is to evaluate the safety, tolerability and efficacy of two multi-dose regimens of UB-421 monotherapy in replacement of HAART in HIV-1 infected adults with virological suppression.
- Trial name
- NCT02369146
- Testing
- UB-421
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- United BioPharma
HIV Infections
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS
To determine the safety and efficacy of zidovudine (AZT) treatment combined with syngeneic or HLA identical allogeneic lymphocyte transfer in the presence of interleukin 2 (IL-2) as a treatment for AIDS.
- Trial name
- NCT00002285
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV1 Infection, HIV 2 Infection
A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test
To evaluate the clinical performance of each analyte (HIV, HBsAg, and Syphilis) on the TruPlex HIV/HepB/Syphilis Rapid Test (TruPlex Test) using capillary blood (fingerstick), EDTA whole blood, EDTA-plasma, and SST-serum samples…
- Conditions
- HIV1 Infection, HIV 2 Infection, Syphilis Infection, Hepatitis B Infection
- Trial name
- NCT07569913
- Testing
- TruPlex HIV/HepB/Syphilis Rapid Test
- Where
- Australia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
HIV Infection
Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)
PHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with…
- Trial name
- PHPC-02 (NCT00918840)
- Testing
- DermaVir, HAART
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Genetic Immunity
HIV -1 Infection
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and…
- Trial name
- NCT07698600
- Testing
- BNT168
- Where
- 4 sites in United States, South Africa
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
HIV Infections
Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection
At the end of 2004 there were more than 40 million people infected Worldwide with HIV, with an estimated 16,000 new infections every day (UNAIDS, 2004).
- Trial name
- NCT00390078
- Testing
- MVA-mBN32, IMVAMUNE
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Bavarian Nordic
HIV-1
An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection
The purpose of this study is to determine the safety and efficacy of administration of a cell-delivered ribozyme gene transfer product to participants with chronic (lasting a long time) Human Immunodeficiency Virus Type 1 (HIV-1)…
- Trial name
- NCT00074997
- Testing
- OZ1, CD34+ cells
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag Pty Ltd
HIV Infections
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
This study will compare the safety and effectiveness of two anti-HIV drug combinations in fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with other anti-HIV drug treatments.
- Trial name
- NCT00002423
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
HIV Infections, Cytopenias
A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
To determine the maximum tolerated dose (MTD) and toxicity of sargramostim (recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF) given by continuous intravenous infusion (CIV) in patients with leukopenia in…
- Trial name
- NCT00002009
- Testing
- Sargramostim
- Where
- 2 sites in United States
- Sponsor
- Sandoz
HIV Infections
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment.
- Trial name
- NCT00002233
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Glaxo Wellcome
HIV
Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection
The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.
- Trial name
- NCT02041247
- Testing
- VAC-3S
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 90 people
- Sponsor
- InnaVirVax
HIV-1 Infection
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo…
- Trial name
- NCT05056974
- Testing
- UB-421, chidamide
- Where
- Taiwan
- Volunteers
- 11 people
- Sponsor
- United BioPharma
HIV Infections
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
The purpose of this study is to see if giving 1592U89 to HIV-infected patients is safe and effective in lowering viral load (level of HIV in the blood) and raising the level of CD4 cells (cells of the body that help fight…
- Trial name
- NCT00002390
- Testing
- Abacavir sulfate
- Where
- 6 sites in France, Germany
- Sponsor
- Glaxo Wellcome
HIV, HIV-1
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have…
- Conditions
- HIV, HIV-1, Human Immunodeficiency Virus
- Trial name
- NCT00298350
- Testing
- GS-9137 - A Novel HIV-1 Integrase Inhibitor
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 278 people
- Sponsor
- Gilead Sciences
Toxoplasmosis, Cerebral, HIV Infections
A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS
To evaluate the effectiveness and toxicity of oral azithromycin and pyrimethamine as acute therapy for toxoplasmic encephalitis in AIDS patients.
- Trial name
- NCT00000966
- Testing
- Azithromycin, Pyrimethamine, Leucovorin calcium
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
HIV Infections
A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients
This study will evaluate the drop in viral load over 10 days of treatment with S-1360 versus placebo in HIV-infected patients who have not previously taken anti-HIV medications.
- Trial name
- NCT00046332
- Testing
- GW810781
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
HIV Infections
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
- Trial name
- NCT00005001
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Agouron Pharmaceuticals